Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial
Crossref DOI link: https://doi.org/10.1186/2051-1426-2-S3-P91
Published Online: 2014-11-06
Published Print: 2014-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kaufman, Howard L
Andtbacka, Robert HI
Collichio, Frances A
Wolf, Michael
Li, Ai
Shilkrut, Mark
Puzanov, Igor
Ross, Merrick
Article History
First Online: 6 November 2014